6533b857fe1ef96bd12b3d0f
RESEARCH PRODUCT
Retinal vein occlusion: current treatment.
Ana GimenoFrancesco BandelloMaurizio Battaglia ParodiRosangela Lattanziosubject
medicine.medical_specialtyRetinal VeinPegaptanibAngiogenesis Inhibitorschemistry.chemical_compoundCentral retinal vein occlusionOcclusionRetinal Vein OcclusionmedicineHumansIntensive care medicineGlucocorticoidsLaser CoagulationVascular diseasebusiness.industryRetinalGeneral Medicinemedicine.diseaseCombined Modality TherapySensory SystemsSurgeryOphthalmologychemistryIntravitreal InjectionsRanibizumabbusinessRetinopathymedicine.drugdescription
Retinal vein occlusion (RVO) is a pathology noted for more than 150 years. Although a lot has been written on the matter, it is still a frequent condition with multifactorial etiopathogenesis with many unclear aspects. The RVO pathogenesis has varied systemic and local implications that make it difficult to elaborate treatment guidelines. The management of the patient with RVO is very complex and a multidisciplinary approach is required in order to identify and correct the associated risk factors. Laser therapy remains the gold standard in RVO, but only modest functional improvement has been shown in branch retinal occlusion forms. Multicenter studies of intravitreal drugs present them as an option to combine with laser. Anti-vascular endothelial growth factor, corticosteroids and sustained-release implants are the future weapons to stop disease progression and get a better visual outcome. Consequently, it is useful to clarify some aspects of the pathology that allow a better patient management. Copyright (C) 2010 S. Karger AG, Basel
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-10-13 | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde |